STAD 2
Based on 1 publication(s) in Google Scholar
STAD 2 is a potent and selective disruptor of PKA-RII, with a Kd of 6.2 nM. STAD 2 disrupts interactions between PKA and AKAP in an isoform-selective manner. STAD 2 displays antimalarial activity through a PKA-independent mechanism.
For research use only. We do not sell to patients.
- Purity : 99.55%
- CAS No.: 1542100-77-5
- Formula: C102H182N24O22
- Molecular Weight:2096.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-N6789
KT5720PKA Inhibitor -
HY-100530D
Rp-cAMPS sodium saltPKA I/II Antagonist -
HY-153967
BLU0588PRKACA Inhibitor -
HY-12306
8-Bromo-cAMP sodium saltPKA Activator -
HY-100530
Rp-cAMPS triethylammonium saltPKA I/II Antagonist -
HY-P3929A
PKI (14-24)amide TFAPKA Inhibitor -
HY-111673
8-CPT-Cyclic AMP sodiumPKA Activator -
HY-B1898
MetadoxinePKA Inhibitor -
HY-18991
CCG215022GRK Inhibitor -
HY-110218
CW 008CREB/PKA Agonist -
HY-P1292
PKG inhibitor peptidePKG Inhibitor -
HY-123396
8-Chloro-cAMPcAMP Analogue
Publications Citing Use of MedChemExpress (MCE) STAD 2
More
Biological Activity
Description
IC50 & Target
PKA-RII[1]
Chemical Information
-
CAS No. 1542100-77-5
-
Appearance Solid
-
Molecular Weight 2096.68
-
Formula C102H182N24O22
-
Color White to off-white
-
Sequence
{PEG3}-Lys-Lys-Leu-Ala-Lys-Phe-Leu-Val-Ser-{Aaa}-Ala-Leu-Lys-{Aaa}-Ala-Leu-Lys (Covalent bridge:Aaa10-Aaa14)
-
Sequence Shortening
{PEG3}-KKLAKFLVS{Aaa}ALK{Aaa}ALK (Covalent bridge:Aaa10-Aaa14)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Eur Heart J
Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis. [Abstract]2025 Oct 27:ehaf836. PMID: 41143464
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (47.69 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang Y, et, al. Isoform-selective disruption of AKAP-localized PKA using hydrocarbon stapled peptides. ACS Chem Biol. 2014 Mar 21;9(3):635-42. [Content Brief]
[2]. Flaherty BR, et, al. The Stapled AKAP Disruptor Peptide STAD-2 Displays Antimalarial Activity through a PKA-Independent Mechanism. PLoS One. 2015 May 26;10(5):e0129239. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.4769 mL | 2.3847 mL | 4.7694 mL | 11.9236 mL |
| 5 mM | 0.0954 mL | 0.4769 mL | 0.9539 mL | 2.3847 mL | |
| 10 mM | 0.0477 mL | 0.2385 mL | 0.4769 mL | 1.1924 mL | |
| 15 mM | 0.0318 mL | 0.1590 mL | 0.3180 mL | 0.7949 mL | |
| 20 mM | 0.0238 mL | 0.1192 mL | 0.2385 mL | 0.5962 mL | |
| 25 mM | 0.0191 mL | 0.0954 mL | 0.1908 mL | 0.4769 mL | |
| 30 mM | 0.0159 mL | 0.0795 mL | 0.1590 mL | 0.3975 mL | |
| 40 mM | 0.0119 mL | 0.0596 mL | 0.1192 mL | 0.2981 mL |
STAD 2 Related Classifications
HY-P2261 Related Classifications
Powered by Bioz